A New Centre For Continuous mRNA Manufacturing

The FDA has recently awarded an $82 million grant to ReciBioPharm and MIT for a three-year research program focused on developing a fully integrated, continuous mRNA manufacturing platform. This program aims to revolutionize the development and production of mRNA technologies, which have played a crucial role in the fight against the COVID-19 pandemic.

Continuous manufacturing is a game-changer in the biopharma industry, as it allows for uninterrupted production and faster response times. The FDA-funded program will serve as a template for continuous manufacturing, paving the way for more efficient and scalable production processes.

ReciBioPharm's platform, known as CP1, is designed to enhance operational effectiveness, accelerate production, and improve product purity and yield. By collaborating with MIT and the FDA, ReciBioPharm aims to push the boundaries of innovation in therapeutic fields.

This partnership between academia, regulatory agencies, and manufacturing organizations holds great promise for the future of medicine. By combining expertise from different sectors, this research program aims to improve society's ability to respond to future pandemics and other healthcare challenges. Explore how this partnership has the potential to reshape the way we produce and distribute mRNA-based therapies, ultimately benefiting patients worldwide.